Connect with us

Published

on

BEVERLY HILLS, Calif. Ariella Morrow, an internal medicine doctor, gradually slid from healthy self-esteem and professional success into the depths of depression.

This story also ran on LAist. It can be republished for free.

Beginning in 2015, she suffered a string of personal troubles, including a shattering family trauma, marital strife, and a major professional setback. At first, sheer grit and determination kept her going, but eventually she was unable to keep her troubles at bay and took refuge in heavy drinking. By late 2020, Morrow could barely get out of bed and didnt shower or brush her teeth for weeks on end. She was up to two bottles of wine a day, alternating it with Scotch whisky.

Sitting in her well-appointed home on a recent autumn afternoon, adorned in a bright lavender dress, matching lipstick, and a large pearl necklace, Morrow traced the arc of her surrender to alcohol: Im not going to drink before 5 p.m. Im not going to drink before 2. Im not going to drink while the kids are home. And then, it was 10 oclock, 9 oclock, wake up and drink. Ariella Morrow, a Los Angeles-area internist, fell into a deep depression and started drinking heavily after a succession of family traumas and a major professional setback. She finally sought help for alcohol dependence and depression at a clinic in Texas.(Bernard J. Wolfson/KFF Health News)

As addiction and overdose deaths command headlines across the nation, the Medical Board of California, which licenses MDs, is developing a new program to treat and monitor doctors with alcohol and drug problems. But a fault line has appeared over whether those who join the new program without being ordered to by the board should be subject to public disclosure.

Patient advocates note that the medical boards primary mission is to protect healthcare consumers and prevent harm, which they say trumps physician privacy.

The names of those required by the board to undergo treatment and monitoring under a disciplinary order are already made public. But addiction medicine professionals say that if the state wants troubled doctors to come forward without a board order, confidentiality is crucial.

Public disclosure would be a powerful disincentive for anybody to get help and would impede early intervention, which is key to avoiding impairment on the job that could harm patients, said Scott Hambleton, president of the Federation of State Physician Health Programs, whose core members help arrange care and monitoring of doctors for substance use disorders and mental health conditions as an alternative to discipline.

But consumer advocates argue that patients have a right to know if their doctor has an addiction. Doctors are supposed to talk to their patients about all the risks and benefits of any treatment or procedure, yet the risk of an addicted doctor is expected to remain a secret? Marian Hollingsworth, a volunteer advocate with the Patient Safety Action Network, told the medical board at a Nov. 14 hearing on the new program.

Doctors are as vulnerable to addiction as anyone else. People who work to help rehabilitate physicians say the rate of substance use disorders among them is at least as high as the rate for the general public, which the federal Substance Abuse and Mental Health Services Administration put at 17.3% in a Nov. 13 report.

Alcohol is a very common drug of choice among doctors, but their ready access to pain meds is also a particular risk.

If you have an opioid use disorder and are working in an operating room with medications like fentanyl staring you down, its a challenge and can be a trigger, said Chwen-Yuen Angie Chen, an addiction medicine doctor who chairs the Well-Being of Physicians and Physicians-in-Training Committee at Stanford Health Care. Its like someone with an alcohol use disorder working at a bar. Email Sign-Up

Subscribe to KFF Health News' free Morning Briefing. Your Email Address Sign Up

From Pioneer to Lagger

California was once at the forefront of physician treatment and monitoring. In 1981, the medical board launched a program for the evaluation, treatment, and monitoring of physicians with mental illness or substance use problems. Participants were often required to take random drug tests, attend multiple group meetings a week, submit to work-site surveillance by colleagues, and stay in the program for at least five years. Doctors who voluntarily entered the program generally enjoyed confidentiality, but those ordered into it by the board as part of a disciplinary action were on the public record.

The program was terminated in 2008 after several audits found serious flaws. One such audit, conducted by Julianne DAngelo Fellmeth, a consumer interest lawyer who was chosen as an outside monitor for the board, found that doctors in the program were often able to evade the random drug tests, attendance at mandatory group therapy sessions was not accurately tracked, and participants were not properly monitored at work sites.

Today, MDs who want help with addiction can seek private treatment on their own or in many cases are referred by hospitals and other health care employers to third parties that organize treatment and surveillance. The medical board can order a doctor on probation to get treatment.

In contrast, the California licensing boards of eight other health-related professions, including osteopathic physicians, registered nurses, dentists, and pharmacists, have treatment and monitoring programs administered under one master contract by a publicly traded company called Maximus Inc. California paid Maximus about $1.6 million last fiscal year to administer those programs.

When and if the final medical board regulations are adopted, the next step would be for the board to open bidding to find a program administrator.

Fall From Grace

Morrows troubles started long after the original California program had been shut down.

The daughter of a prominent cosmetic surgeon, Morrow grew up in Palm Springs in circumstances she describes as beyond privileged. Her father, David Morrow, later became her most trusted mentor.

But her charmed life began to fall apart in 2015, when her father and mother, Linda Morrow, were indicted on federal insurance fraud charges in a well-publicized case. In 2017, the couple fled to Israel in an attempt to escape criminal prosecution, but later they were both arrested and returned to the United States to face prison sentences.

The legal woes of Morrows parents, later compounded by marital problems related to the failure of her husbands business, took a heavy toll on Morrow. She was in her early 30s when the trouble with her parents started, and she was working 16-hour days to build a private medical practice, with two small children at home. By the end of 2019, she was severely depressed and turning increasingly to alcohol. Then, the loss of her admitting privileges at a large Los Angeles hospital due to inadequate medical record-keeping shattered what remained of her self-confidence.

Morrow, reflecting on her experience, said the very strengths that propel doctors through medical school and keep them going in their careers can foster a sense of denial. We are so strong that our strength is our greatest threat. Our power is our powerlessness, she said. Morrow ignored all the flashing yellow lights and even the red light beyond which serious trouble lay: I blew through all of it, and I fell off the cliff.

By late 2020, no longer working, bedridden by depression, and drinking to excess, she realized she could no longer will her way through: I finally said to my husband, I need help. He said, I know you do.

Ultimately, she packed herself off to a private residential treatment center in Texas. Now sober for 21 months, Morrow said the privacy of the addiction treatment she chose was invaluable because it shielded her from professional scrutiny.

I didnt have to feel naked and judged, she said.

Morrow said her privacy concerns would make her reluctant to join a state program like the one being considere by the medical board.

Physician Privacy vs. Patient Protection

The proposed regulations would spare doctors in the program who were not under board discipline from public disclosure as long as they stayed sober and complied with all the requirements, generally including random drug tests, attendance at group sessions, and work-site monitoring. If the program put a restriction on a doctors medical license, it would be posted on the medical boards website, but without mentioning the doctors participation in the program.

Yet even that might compromise a doctors career since having a restricted license for unspecified reasons could have many enduring personal and professional implications, none positive, said Tracy Zemansky, a clinical psychologist and president of the Southern California division of Pacific Assistance Group, which provides support and monitoring for physicians.

Zemansky and others say doctors, just like anyone else, are entitled to medical privacy under federal law, as long as they havent caused harm.

Many who work in addiction medicine also criticized the proposed new program for not including mental health problems, which often go hand in hand with addiction and are covered by physician health programs in other states.

To forgo mental health treatment, I think, is a grave mistake, Morrow said. For her, depression and alcoholism were inseparable, and the residential program she attended treated her for both.

Another point of contention is money. Under the current proposal, doctors would bear all the costs of the program.

The initial clinical evaluation, plus the regular random drug tests, group sessions, and monitoring at their work sites could cost participants over $27,000 a year on average, according to estimates posted by the medical board. And if they were required to go for 30-day inpatient treatment, that would add an additional $40,000 plus nearly $36,000 in lost wages.

People who work in the field of addiction medicine believe that is an unfair burden. They note that most programs for physicians in other states have outside funding to reduce the cost to participants.

The cost should not be fully borne by the doctors, because there are many other people that are benefiting from this, including the board, malpractice insurers, hospitals, the medical association, said Greg Skipper, a semi-retired addiction medicine doctor who ran Alabamas state physician health program for 12 years. In Alabama, he said, those institutions contribute to the program, significantly cutting the amount doctors have to pay.

The treatment program that Morrow attended in spring of 2021, at The Menninger Clinic in Houston, cost $80,000 for a six-week stay, which was covered by a concerned family member. It saved my life, she said.

Though Morrow had difficulty maintaining her sobriety in the first year after treatment, she has now been sober since April 2, 2022. These days, Morrow regularly attends therapy and Alcoholics Anonymous and has pivoted to become an addiction medicine doctor.

I am a better doctor today because of my experience no question, Morrow said. I am proud to be a doctor whos an alcoholic in recovery.

This article was produced by KFF Health News, which publishes California Healthline, an editorially independent service of the California Health Care Foundation.

Bernard J. Wolfson: bwolfson@kff.org, @bjwolfson Related Topics California Health Industry Mental Health States Doctors Hospitals Substance Misuse Contact Us Submit a Story Tip

Continue Reading

UK

Mother of girl operated on 17 times by now-suspended surgeon fears she may never walk again

Published

on

By

Mother of girl operated on 17 times by now-suspended surgeon fears she may never walk again

The mother of a young girl operated on 17 times by a now-suspended surgeon has told Sky News she’s “angry and so upset” and fears her daughter may never walk again.

Her child is only eight years old and now needs further surgery, including a hip replacement.

She was one of nine patients whose treatment fell below the expected standard at Addenbrooke’s Hospital in Cambridge.

The Department of Health told Sky News the situation is “incredibly concerning”.

The little girl’s case was uncovered following an external review into the specialist paediatric surgeon who has since been suspended.

Sky's Laura Bundock spoke to the girl's mum (R), who has asked not to be named
Image:
Sky’s Laura Bundock spoke to the girl’s mum (R), who has asked not to be named

The child was born with hip dysplasia, a condition affecting the hip socket, which can usually be fixed. But issues with her operations have left her using a wheelchair and crutches.

Her mother, who’s asked not to be named, said: “It’s like a big limp. She is not stable and can’t balance on that leg, so she always has to have an aide with her because she would fall over and hurt herself.”

Notes given to the family list a catalogue of serious issues involving the surgeon’s treatment, including “problems with both judgement and technique”.

Cambridge University Hospitals Trust is now reviewing 800 patients treated by the same surgeon.

Of these, 700 are children who underwent planned orthopaedic surgery. Another 100 are patients who received emergency trauma surgery.

Addenbrooke's Hospital. File pic: PA
Image:
Addenbrooke’s Hospital in Cambridge. File pic: PA

What’s troubling the family now is that concerns were first raised about the surgeon a decade ago.

The mother said: “My daughter wasn’t born until 2016, so had the trust acted on this correctly, my daughter probably would never have seen that consultant and she would have probably been fine.”

An independent external investigation team is assessing whether issues could have been addressed earlier.

Sky News has spoken to several clinicians working at Addenbrooke’s. One is so concerned that they’ve contacted Health Secretary Wes Streeting, claiming the damage caused was “all avoidable” and that “many lives have been ruined”.

Read more on Sky News:
Putin says US is serious about Greenland
European allies not united on armed deployment in Ukraine
Woman charged with stalking McCann family

Addenbrooke's
Image:
Tammy Harrison was operated on by the now-suspended surgeon

‘The pain was all the time’

Tammy Harrison is 12 years old and has cerebral palsy. She was also operated on by the now-suspended surgeon.

There’s no evidence of any wrongdoing yet, but one of her operations didn’t work and left her in agonising pain.

“It felt like I was being stabbed. The pain was all the time, I couldn’t move and I couldn’t even get out of bed,” Tammy said.

She’s now unable to sit on the floor, and her legs are different lengths.

Her mum, Lynn, said she became worried about her care shortly after the operation.

Addenbrooke's
Image:
Tammy’s mother Lynn Harrison

She said: “The pain level wasn’t deteriorating. It just seemed like she was getting worse. And at the six-week review, I asked, why is she still in so much pain? And it was just brushed underneath her carpet.”

Cambridge University Hospitals say they’re deeply sorry and will do everything they can to support families and patients.

Lawyers representing one of the families say the numbers potentially impacted are “staggering”.

Medical negligence solicitor at Osborne Law, Jodi Newton, said: “It’s clearly shocking in terms of the types of patients involved, in that most of those are children, and numbers – what we don’t know is whether there is going to be more patients than those already identified. It could be in its thousands.”

Families are now anxiously waiting for answers and the truth about their children’s treatment.

‘I wish I had spoken up more’

Lynn Harrison said: “I’m glad it’s come to light, and I wasn’t being an overprotective mum.

“But I am angry. I wish I had spoken up more and pushed further because other patients might not have had to suffer.”

Continue Reading

Technology

U.S. tech giants are betting big on humanoid robots — but China’s already ahead, analysts say

Published

on

By

U.S. tech giants are betting big on humanoid robots — but China's already ahead, analysts say

Unitree’s G1 robot at the Mobile World Congress 2025 in Barcelona, Spain, on March 6, 2025.

Nurphoto | Nurphoto | Getty Images

American tech giants like Tesla and Nvidia are racing to develop humanoid robots, stressing their importance to the future economy. But analysts warn they are already at risk of losing out to China.

So-called humanoid robots — artificial intelligence-powered machines designed to resemble humans in appearance and movement — are expected to provide a range of use cases, such as filling industrial and service sector jobs.  

Investor excitement surrounding the robots has been mounting amid increased mentions from tech leaders like Nvidia’s Jensen Huang, who ushered in “the age of generalist robotics” earlier this month when announcing a new portfolio of technologies for humanoid robot development.

In the manufacturing of the robots themselves, Tesla’s humanoid robot project, Optimus, appears to be leading in the U.S., with CEO Elon Musk announcing plans to produce about 5,000 units this year.

While Musk’s ambitious plans could give it a leg up on U.S. competitors like Apptronik and Boston Dynamics that are yet to hit the mass market, he will face stiff competition from a familiar source: China. 

Jensen Huang, co-founder and chief executive officer of Nvidia, speaks about humanoids during the 2025 CES event in Las Vegas on Jan. 6, 2025.

Bridget Bennett | Bloomberg | Getty Images

Hangzhou-based Unitree Robotics last month briefly sold two humanoid robots to consumers on the e-commerce platform JD.com, as per local media. Meanwhile, Shanghai-based robotics startup Agibot, also known as Zhiyuan Robotics, has matched Optimus’s goal to produce 5,000 robots this year, according to the South China Morning Post

As Chinese electric vehicle companies like BYD begin outpacing Tesla’s growth and undercutting its prices, experts say a similar dynamic could play out in humanoid robotics. 

“China has the potential to replicate its disruptive impact from the EV industry in the humanoid space. However, this time the disruption could extend far beyond a single industry, potentially transforming the labor force itself,” said Reyk Knuhtsen, analyst at SemiAnalysis, an independent research and analysis company specializing in semiconductors and AI.

Dancing on the competition?

In a research note in February, Morgan Stanley estimated that current building costs of humanoid robots could range from $10,000 to $300,000 per unit, given different configurations and downstream application requirements.

However, Chinese companies are already undercutting U.S. competitors in terms of price thanks to superior economies of scale and manufacturing capabilities, according to Knuhtsen. 

For example, Unitree released its G1 humanoid robot for consumers in May with a starting price of $16,000. In comparison, Morgan Stanley estimates that the selling cost of Tesla’s Optimus Gen2 humanoid robot could be around $20,000, but only if the company is able to scale, shorten its research and development cycle, and use cost-effective components from China.

Unitree made a major splash in the robot’s space in January when 16 of its highest-performing H1 humanoid robots joined a group of human dancers to celebrate the Lunar New Year in a demonstration broadcast on national television.

But there are signs that China’s progress in robots go much further. Morgan Stanley’s February research note found that the country has led the world in patent filings mentioning “humanoid” over the past five years, with 5,688 patents compared with 1,483 from the United States.

Large players such as Xiaomi and EV makers, such as BYD, Chery, and Xpeng, are also involved in the humanoid robot space. 

“Our research suggests China continues to show the most impressive progress in humanoid robotics where startups are benefitting from established supply chains, local adoption opportunities, and strong degrees of national government support,” the note said.

Beijing has increasingly backed the space, with government departments promoting their development. In 2023, the Ministry of Industry and Information Technology issued guidelines for the space, calling for “production at scale” by 2025.

'Very fast' decline in component costs of humanoid robots in next few years, says analyst

According to Ming Hsun Lee, head of Greater China automotive and industrials research at BofA Global Research, China sees humanoid robots as an important industry because of their potential to mitigate looming labor shortages. 

“I think in the short-term, three to four years, we will see humanoid robots initially applied in production lines to compare some workers, and in the midterm, we will see them gradually spread into the service industry,” he said. 

Musk predicted that he’d have over 1,000, or a few thousand, Optimus robots working at Tesla in 2025. According to Chinese state media, EV makers like BYD and Geely have already deployed some of Unitree’s humanoid robots at their factories.  

Lee said that increased adoption will coincide with a “very fast” decline in component costs, also noting that China owns around 70% of the supply chain for these components. 

According to a report by SemiAnalysis earlier this month, the Unitree G1 — “the only viable humanoid robot on the market” — is entirely decoupled from American components.

The report warns that China is the only country positioned to reap the economic awards of intelligent robotics systems, including humanoid robots, which “poses an existential threat to the US as it is outcompeted in all capacities.” 

“To catch up, U.S. players must rapidly mobilize a strong manufacturing and industrial base, whether domestically or through allied nations … For Tesla and similar firms, it may be wise to begin reshoring or ‘friendshoring’ their component sourcing and manufacturing to reduce reliance on China,” said SemiAnalysis’ Knuhtsen. 

Bank of America analysts predicted in a research note this month that the deployment of humanoid robots will accelerate rapidly, aided by the development of AI, with global annual sales reaching 1 million units by 2030 and 3 billion humanoid robots in operation by 2060. 

Continue Reading

Business

WH Smith high street arm sold to Hobbycraft owner in £76m deal

Published

on

By

WH Smith high street arm sold to Hobbycraft owner in £76m deal

WH Smith has sold its 233-year old high street business to the owner of Hobbycraft in a £76m deal.

Sky News revealed in January how a sales process was under way for the arm, which employs roughly 5,000 people and has 480 stores.

Modella Capital won the final stage of the auction process in a run off against Alteri investors – both specialists in turning around troubled retailers.

Money latest: Time running out for EV drivers to save £195

The deal will see the WH Smith name erased from town centres to become TGJones.

The sale allows the WH Smith business to focus fully on its lucrative travel retail arm.

That has around 1,200 stores, based mainly at airports and railway stations, in 32 countries globally and accounts for 85% of group profits.

Chief executive Carl Cowling said: “Given our rapid international growth, now is the right time for a new owner to take the High Street business forward and for the WH Smith leadership team to focus exclusively on our Travel business”.

There was no word on what the new owners may do to bolster profitability, with a question mark firmly hanging over employment and the store estate – often the subject of criticism over a perceived lack of investment.

WH Smith’s statement said: “All stores, colleagues, assets and liabilities of the High Street business will move under Modella Capital’s ownership as part of the Transaction.

Read more from Sky News:
Port giant ‘discredited’ by minister despite £1bn investment
Trump tariffs: German town frets over VW future
Boohoo’s Debenhams renaming opposed by Ashley

“Under this new ownership, the business will be led by Sean Toal, currently CEO of the High Street business. The High Street business will operate for a short transitional period under the WHSmith brand whilst the business rebrands as TGJones.”

The sale to Modella represents an enterprise value of £76m on a cash and debt-free basis but will see WH Smith secure an estimated £25m on a net basis after several costs associated with the sale are accounted for.

Shares fell by more than 1% at the open.

Continue Reading

Trending